SharonARiddlerMD

Infectious Disease • Pittsburgh, PA

HIV/AIDS Medicine

Professor, Medicine, University of Pittsburgh School of Medicine

Join to view full profile

Dr. Riddler is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Riddler's full profile

Already have an account?

Office
3601 Fifth Avenue
Pact - Falk, Suite 700
Pittsburgh, PA 15213
Phone+1 412-647-7228

Education & Training

UPMC Medical EducationFellowship, Infectious Disease, 1991 - 1994
University of Missouri-Kansas City School of MedicineResidency, Internal Medicine, 1986 - 1990
Medical College of WisconsinClass of 1986

Certifications & Licensure

PA State Medical License 1991 - 2024
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Infectious Disease

Awards, Honors, & Recognition

Physician Practice Connections Recognition Program National Committee for Quality Assurance, 2012-2015
Patient-Centered Medical Home Recognition Program National Committee for Quality Assurance, 2012-2015
CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2011

Clinical Trials

Effects of Changing HIV Therapy at Lower Versus Higher Viral Loads
Completed
Phase 2
Comparing the Safety, Effectiveness, and Tolerability of Three Anti-HIV Drug Regimens for Treatment-Naive Patients
Completed
Phase 3
HIV Vaccine Designed for HIV Infected Adults Taking Anti-HIV Drugs Start of enrollment: 2003 Feb 01
Completed
Phase 1
Autologous Dendritic Cell Vaccine in HIV1 Infection Start of enrollment: 2007 Jul 01
Completed
Phase 1, Phase 2
Observational Study of HIV Infected Women Previously Enrolled in Other Microbicide Trials Start of enrollment: 2008 Aug 25
Completed
Pilot Study of Adding Raltegravir (MK-0518) to Antiretroviral Therapy in Patients With Low Level Viremia Start of enrollment: 2007 Oct 01
Completed
Not Applicable
Bone Mineral Density Substudy - An Ancillary Study to MTN-003 Start of enrollment: 2009 Nov 01
Completed
IMPAACT 1077HS: Examining Benefits of HAART Continuation in Postpartum Women Start of enrollment: 2010 Jan 01
Completed
Phase 4
FTC/RPV/TDF on T-Cell Activation, CD4+ T-Cell Count, Inflammatory Biomarkers and Viral Reservoir Start of enrollment: 2013 Apr 25
Completed
Phase 4
Dipyridamole for Immune Activation in HIV Start of enrollment: 2014 Jul 01
Completed
Phase 1, Phase 2
Comparison of Dendritic Cell-Based Therapeutic Vaccine Strategies for HIV Functional Cure Start of enrollment: 2018 Nov 30
Active, not recruiting
Phase 1
Safety and Pharmacokinetic Study of Tenofovir Alafenamide (TAF)/Elvitegravir (EVG) Administered Rectally Start of enrollment: 2019 Dec 11
Completed
Phase 1
A Study to Evaluate the Effects of Cenicriviroc Mesylate on Arterial Inflammation in People Living With HIV Start of enrollment: 2023 May 30
Active, not recruiting
Phase 2
Roles: Contact
The Study of Immunization in People Living With HIV Undergoing an ATI for Elicitation of VRC01-lineage Antibodies Start of enrollment: 2024 Jan 03
Recruiting
Phase 1
Roles: Contact
Join now to see all

Publications & Presentations

PubMed

252 citations
Association between highly active antiretroviral therapy and hypertension in a large cohort of men followed from 1984 to 2003.
Eric C. Seaberg, Alvaro Muñoz, Ming Lu, Roger Detels, Joseph B. Margolick
AIDS. 2005-06-10
914 citations
The major genetic determinants of HIV-1 control affect HLA class I peptide presentation
Florencia Pereyra, Xiaoming Jia, Paul J. McLaren, Amalio Telenti, de Bakker Pi
Science. 2010-12-10
180 citations
HIV-1 DNA Decay Dynamics in Blood During More Than a Decade of Suppressive Antiretroviral Therapy
Guillaume Besson, Christina M. Lalama, Ronald J. Bosch, Rajesh T. Gandhi, Margaret A. Bedison
Clinical Infectious Diseases. 2014-11-01

Journal Articles

Clinical and Virologic Outcomes Following Initiation of Antiretroviral Therapy Among Seroconverters in the MTN-020/ASPIRE Phase III Trial of the Dapivirine Vaginal Ring
Sharon Riddler, MD, Clinical Infectious Diseases

Press Mentions

Minimal Antibody Response in Imbokodo Compels Change of Course for HIV Vaccine ResearchJuly 31st, 2022
Trial of Three mRNA HIV Vaccines LaunchedMarch 15th, 2022
Westmoreland Commissioners to Host 2nd Info Session on Covid-19 VaccineMarch 29th, 2021
Join now to see all

Grant Support

Immunotherapy With Autologous Hiv-Loaded Dendritic CellsNational Institute Of Allergy And Infectious Diseases2010–2011
RAND PHI Eval Immuniz W/Highly Conserved HIV-1 DER PEPT Influ MatrixNational Center For Research Resources2005
An Assessment Of Oral Mucosal Immunity In HIV-1 Infection - Version 10National Center For Research Resources2005
ACTG A5079: A Prospective, Multicenter, Randomized, Placebo-Controlled Trial OfNational Center For Research Resources2005
ACTG A5142: A Phase III, Randomized, Open-Label Comparison Of Lopinavir/National Center For Research Resources2004–2005
Immuniz. W/Highly Conserved HIV-1 Der. Influ. MatrixNational Center For Research Resources2004
Assessment Of Oral Mucosal Immunity In HIV-1 InfectionNational Center For Research Resources2004
A Prospective Analysis Of Body Composition In Men Enrolled In The MulticenterNational Center For Research Resources2004
T 20 W/ Abacavir Amprenavir, Ritonavir, Efavirenz In HIVNational Center For Research Resources2000–2002
Multicenter 34 Week Study Of Invinavir/Nelfinavir In HIV 1 Seropositive PatientsNational Center For Research Resources1998–2000
Double Blind Placebo Controlled Study Of DMP 266 And Indinvir In HIV+ PatientsNational Center For Research Resources1997–1999